Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Common Equity (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Common Equity for 9 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Common Equity fell 17.56% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 billion through Dec 2025, down 17.56% year-over-year, with the annual reading at $1.0 billion for FY2025, 17.56% down from the prior year.
  • Common Equity for Q4 2025 was $1.0 billion at Denali Therapeutics, up from $926.2 million in the prior quarter.
  • The five-year high for Common Equity was $1.5 billion in Q1 2024, with the low at $811.3 million in Q3 2022.
  • Average Common Equity over 5 years is $1.1 billion, with a median of $1.0 billion recorded in 2022.
  • The sharpest move saw Common Equity surged 113.62% in 2021, then fell 29.75% in 2025.
  • Over 5 years, Common Equity stood at $962.3 million in 2021, then grew by 8.33% to $1.0 billion in 2022, then decreased by 1.1% to $1.0 billion in 2023, then rose by 19.28% to $1.2 billion in 2024, then fell by 17.56% to $1.0 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $1.0 billion, $926.2 million, and $1.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.